Literature DB >> 7739500

The natural history of multiple sclerosis.

B G Weinshenker1.   

Abstract

The natural history of MS is highly variable. There is substantial heterogeneity in the clinical manifestations but, at this point, it is reasonable to consider all idiopathic inflammatory demyelinating diseases of the central nervous system as representing a spectrum of the same disease. In large populations, 20% to 40% have "benign disease," defined as having less than moderate disability after 10 years. Benign is a potentially misleading term because many of these patients subsequently will become disabled. Half will develop progressive MS within 10 years and will require some form of walking aid within 15 years following the onset of MS. Survival is not greatly shortened in mildly disabled patients, but the observed mortality is increased four-fold over the general population in patients with advanced disability. Patients with the greatest risk of disability are those with PP MS and RR patients who are older at onset, have pyramidal or cerebellar involvement at onset, and who have frequent or prolonged attacks with incomplete recovery. The biological basis for the variation in the course of MS is understood only in a very limited way. The short- and long-term course of MS may be determined by different biological variables. Short-term benefit in clinical trials should not be assumed to indicate long-term reduction in the risk of permanent disability.

Entities:  

Mesh:

Year:  1995        PMID: 7739500

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  42 in total

1.  Drug treatment of multiple sclerosis

Authors: 
Journal:  West J Med       Date:  2000-12

Review 2.  Drug treatment of multiple sclerosis.

Authors:  C H Polman; B M Uitdehaag
Journal:  BMJ       Date:  2000 Aug 19-26

3.  Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study).

Authors:  O Fernández; V Fernández; T Arbizu; G Izquierdo; I Bosca; R Arroyo; J A García Merino; E de Ramón
Journal:  J Neurol       Date:  2010-04-10       Impact factor: 4.849

Review 4.  The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy.

Authors:  Alessandra Gaeta; Robert C Hider
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

5.  Characterization of a severe parenchymal phenotype of experimental autoimmune encephalomyelitis in (C57BL6xB10.PL)F1 mice.

Authors:  Michael D Carrithers; Lisette M Carrithers; Jan Czyzyk; Octavian Henegariu
Journal:  J Neuroimmunol       Date:  2007-05-18       Impact factor: 3.478

Review 6.  Efficacy and safety of prolonged immunomodulatory treatment with interferon beta.

Authors:  T L Demina; N V Khachanova; M V Davydovskaya; N F Popova; E I Gusev
Journal:  Neurosci Behav Physiol       Date:  2009-06

Review 7.  Defining Disease Activity and Response to Therapy in MS.

Authors:  Ulrike W Kaunzner; Mais Al-Kawaz; Susan A Gauthier
Journal:  Curr Treat Options Neurol       Date:  2017-05       Impact factor: 3.598

8.  1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS.

Authors:  J Suhy; W D Rooney; D E Goodkin; A A Capizzano; B J Soher; A A Maudsley; E Waubant; P B Andersson; M W Weiner
Journal:  Mult Scler       Date:  2000-06       Impact factor: 6.312

Review 9.  The pathological spectrum of CNS inflammatory demyelinating diseases.

Authors:  Wei Hu; Claudia F Lucchinetti
Journal:  Semin Immunopathol       Date:  2009-09-25       Impact factor: 9.623

10.  Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tablets.

Authors:  Claudio Gasperini; Serena Ruggieri; Carlo Pozzilli
Journal:  Ther Clin Risk Manag       Date:  2010-09-07       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.